PMID- 37233878
OWN - NLM
STAT- MEDLINE
DCOM- 20230619
LR  - 20231206
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 40
IP  - 7
DP  - 2023 Jul
TI  - Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle 
      East: Review of the 2022 EVIDENT Summit.
PG  - 2965-2984
LID - 10.1007/s12325-023-02529-7 [doi]
AB  - Type 2 diabetes mellitus (T2DM) and hypertension are leading risk factors for 
      death and disability in the Middle East. Both conditions are highly prevalent, 
      underdiagnosed and poorly controlled, highlighting an urgent need for a roadmap 
      to overcome the barriers to optimal glycaemic and blood pressure management in 
      this region. This review provides a summary of the Evidence in Diabetes and 
      Hypertension Summit (EVIDENT) held in September 2022, which discussed current 
      treatment guidelines, unmet clinical needs and strategies to improve treatment 
      outcomes for patients with T2DM and hypertension in the Middle East. Current 
      clinical guidelines recommend strict glycaemic and blood pressure targets, 
      presenting several treatment options to achieve and maintain these targets and 
      prevent complications. However, treatment targets are infrequently met in the 
      Middle East, largely due to high clinical inertia among physicians and low 
      medication adherence among patients. To address these challenges, clinical 
      guidelines now provide individualised therapy recommendations based on drug 
      profiles, patient preferences and management priorities. Efforts to improve the 
      early detection of prediabetes, T2DM screening and intensive, early glucose 
      control will minimise long-term complications. Physicians can use the T2DM Oral 
      Agents Fact Checking programme to help navigate the wide range of treatment 
      options and guide clinical decision-making. Sulfonylurea agents have been used 
      successfully to manage T2DM; a newer agent, gliclazide MR (modified release 
      formulation), has the advantages of a lower incidence of hypoglycaemia with no 
      risk of cardiovascular events, weight neutrality and proven renal benefits. For 
      patients with hypertension, single-pill combinations have been developed to 
      improve efficacy and reduce treatment burden. In conjunction with pragmatic 
      treatment algorithms and personalised therapies, greater investments in disease 
      prevention, public awareness, training of healthcare providers, patient 
      education, government policies and research are needed to improve the quality of 
      care of patients with T2DM and/or hypertension in the Middle East.
CI  - (c) 2023. The Author(s).
FAU - Al Saleh, Yousef
AU  - Al Saleh Y
AUID- ORCID: 0000-0002-5875-0950
AD  - Dr. Mohammad AlFagih Hospital, Riyadh, Kingdom of Saudi Arabia. 
      yousef.alsaleh@dmf.med.sa.
FAU - Al Busaidi, Noor
AU  - Al Busaidi N
AD  - National Diabetes and Endocrine Centre, Royal Hospital, Muscat, Oman.
AD  - Oman Diabetes Association, Muscat, Oman.
FAU - Al Dahi, Waleed
AU  - Al Dahi W
AD  - Kuwait Diabetes Society, Kuwait City, Kuwait.
FAU - Almajnoni, Munawar
AU  - Almajnoni M
AUID- ORCID: 0000-0001-5992-1881
AD  - Department of Cardiology, My Clinic, Jeddah, Kingdom of Saudi Arabia.
AD  - Saudi Society of Echocardiography, Jeddah, Kingdom of Saudi Arabia.
FAU - Mohammed, Al Saeed
AU  - Mohammed AS
AUID- ORCID: 0000-0002-5422-155X
AD  - Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
AD  - Bahrain Defence Force Royal Medical Services, Riffa, Kingdom of Bahrain.
FAU - Alshali, Khalid
AU  - Alshali K
AUID- ORCID: 0000-0002-7856-9753
AD  - Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, 
      Kingdom of Saudi Arabia.
FAU - Al-Shamiri, Mostafa
AU  - Al-Shamiri M
AUID- ORCID: 0000-0003-3443-001X
AD  - Department of Cardiac Sciences, King Saud University, Riyadh, Kingdom of Saudi 
      Arabia.
FAU - Al Sifri, Saud
AU  - Al Sifri S
AD  - Al Hada Armed Forces Hospital, Taif, Kingdom of Saudi Arabia.
FAU - Arafah, Mohammed
AU  - Arafah M
AUID- ORCID: 0000-0002-6664-4584
AD  - Dallah Cardiac Centre, Riyadh, Kingdom of Saudi Arabia.
FAU - Chan, Siew Pheng
AU  - Chan SP
AUID- ORCID: 0000-0002-7031-7594
AD  - Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
FAU - El-Tamimi, Hassan
AU  - El-Tamimi H
AD  - Mohammed Bin Rashid University of Medicine and Health Science, Dubai, United Arab 
      Emirates.
AD  - Department of Cardiology, Mediclinic Parkview Hospital, Dubai, United Arab 
      Emirates.
FAU - Hafidh, Khadija
AU  - Hafidh K
AUID- ORCID: 0000-0002-3632-4336
AD  - Diabetes Unit, Rashid Hospital, Dubai, United Arab Emirates.
FAU - Hassanein, Mohamed
AU  - Hassanein M
AUID- ORCID: 0000-0001-6598-6972
AD  - Department of Endocrinology, Dubai Hospital, Dubai, United Arab Emirates.
FAU - Shaaban, Ashraf
AU  - Shaaban A
AD  - Diabetes Control Centre, Ghassan Najib Pharaon Hospital, Jeddah, Kingdom of Saudi 
      Arabia.
FAU - Sultan, Ali
AU  - Sultan A
AUID- ORCID: 0000-0002-7265-4279
AD  - Diabetes Centre, International Medical Centre Hospital, Jeddah, Kingdom of Saudi 
      Arabia.
FAU - Grassi, Guido
AU  - Grassi G
AD  - Clinica Medica, University of Milano-Bicocca, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230526
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Sulfonylurea Compounds)
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Risk Factors
MH  - *Hypertension/complications/drug therapy
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Blood Pressure
PMC - PMC10271906
OTO - NOTNLM
OT  - Adherence
OT  - Clinical inertia
OT  - Gliclazide
OT  - Hypertension
OT  - Individualised therapy
OT  - Middle East
OT  - Single-pill combination
OT  - Type 2 diabetes mellitus
COIS- Yousef Al Saleh received honoraria from and was on advisory boards for Lilly, 
      Novo Nordisk, Sanofi Aventis and Servier. Siew Pheng Chan received honoraria as a 
      speaker or member of advisory boards for AstraZeneca, Boehringer Ingelheim, 
      Merck, Novo Nordisk, Novartis, Sanofi Aventis, Servier and Zuellig Pharma. Noor 
      Al Busaidi, Waleed Al Dahi, Munawar Almajnoni, Al Saeed Mohammed, Khalid Alshali, 
      Mostafa Al-Shamiri, Saud Al Sifri, Mohammed Arafah, Hassan El-Tamimi, Khadija 
      Hafidh, Mohamed Hassanein, Ashraf Shaaban, Ali Sultan and Guido Grassi declare no 
      conflicts of interest.
EDAT- 2023/05/26 13:09
MHDA- 2023/06/19 13:08
PMCR- 2023/05/26
CRDT- 2023/05/26 11:10
PHST- 2023/02/27 00:00 [received]
PHST- 2023/04/20 00:00 [accepted]
PHST- 2023/06/19 13:08 [medline]
PHST- 2023/05/26 13:09 [pubmed]
PHST- 2023/05/26 11:10 [entrez]
PHST- 2023/05/26 00:00 [pmc-release]
AID - 10.1007/s12325-023-02529-7 [pii]
AID - 2529 [pii]
AID - 10.1007/s12325-023-02529-7 [doi]
PST - ppublish
SO  - Adv Ther. 2023 Jul;40(7):2965-2984. doi: 10.1007/s12325-023-02529-7. Epub 2023 
      May 26.